Microbiome therapeutics company Seres Therapeutics has announced that a Phase IIb study of its potential ulcerative colitis (UC) candidate SER-287 failed to meet its primary endpoint.
Seres Therapeutics has signed an agreement with Nestlé Health Science to co-market the former’s investigational treatment, SER-109, for recurrent Clostridioides difficile infection (CDI) in the US and Canada.
AstraZeneca has formed a research alliance with US-based Seres Therapeutics to explore the use of microbiome in boosting the efficacy of cancer immunotherapy.